CN109675042B - 用于治疗和/或预防流感的组合物、方法和用途 - Google Patents
用于治疗和/或预防流感的组合物、方法和用途 Download PDFInfo
- Publication number
- CN109675042B CN109675042B CN201910105492.3A CN201910105492A CN109675042B CN 109675042 B CN109675042 B CN 109675042B CN 201910105492 A CN201910105492 A CN 201910105492A CN 109675042 B CN109675042 B CN 109675042B
- Authority
- CN
- China
- Prior art keywords
- influenza
- anhydride
- protein
- solution
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 133
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 130
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 98
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 87
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 23
- 230000009385 viral infection Effects 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims description 98
- 239000003814 drug Substances 0.000 claims description 35
- 208000037797 influenza A Diseases 0.000 claims description 34
- 230000004048 modification Effects 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 32
- 102000008192 Lactoglobulins Human genes 0.000 claims description 29
- 108010060630 Lactoglobulins Proteins 0.000 claims description 29
- 229910019142 PO4 Inorganic materials 0.000 claims description 27
- 239000010452 phosphate Substances 0.000 claims description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- CCTOEAMRIIXGDJ-UHFFFAOYSA-N 4-hydroxy-2-benzofuran-1,3-dione Chemical group OC1=CC=CC2=C1C(=O)OC2=O CCTOEAMRIIXGDJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- 239000012460 protein solution Substances 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- 206010064097 avian influenza Diseases 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 11
- 150000008065 acid anhydrides Chemical class 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 208000037798 influenza B Diseases 0.000 claims description 9
- 229960003752 oseltamivir Drugs 0.000 claims description 9
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 9
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 9
- 229960001084 peramivir Drugs 0.000 claims description 9
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 8
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 8
- 229960003805 amantadine Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- -1 ranamivir Chemical compound 0.000 claims description 8
- 229960000888 rimantadine Drugs 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 229960001028 zanamivir Drugs 0.000 claims description 8
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 7
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 claims description 6
- 201000010740 swine influenza Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- 235000011008 sodium phosphates Nutrition 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 206010069767 H1N1 influenza Diseases 0.000 claims 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 25
- 238000002474 experimental method Methods 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 230000001932 seasonal effect Effects 0.000 abstract description 8
- 238000012404 In vitro experiment Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000035772 mutation Effects 0.000 abstract description 2
- 102000004407 Lactalbumin Human genes 0.000 abstract 1
- 108090000942 Lactalbumin Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 82
- 241001112090 Pseudovirus Species 0.000 description 52
- 241000700605 Viruses Species 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 21
- 230000004083 survival effect Effects 0.000 description 21
- 101710154606 Hemagglutinin Proteins 0.000 description 19
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 19
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 19
- 101710176177 Protein A56 Proteins 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 13
- 239000000185 hemagglutinin Substances 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 11
- 102000008100 Human Serum Albumin Human genes 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108010006232 Neuraminidase Proteins 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 102000005348 Neuraminidase Human genes 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 9
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 8
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 229940014800 succinic anhydride Drugs 0.000 description 7
- 208000002979 Influenza in Birds Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 238000007664 blowing Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010061514 sialic acid receptor Proteins 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000037801 influenza A (H1N1) Diseases 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002911 sialidase inhibitor Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241000134304 Influenza A virus H3N2 Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000037802 influenza A (H3N2) Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000004364 Benzylated hydrocarbon Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241000401051 Influenza D virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 101710150593 Protein beta Proteins 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000150287 Thailand orthohantavirus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 229950004244 laninamivir Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000024275 uncoating of virus Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pulmonology (AREA)
Abstract
Description
Claims (41)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910105492.3A CN109675042B (zh) | 2019-02-01 | 2019-02-01 | 用于治疗和/或预防流感的组合物、方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910105492.3A CN109675042B (zh) | 2019-02-01 | 2019-02-01 | 用于治疗和/或预防流感的组合物、方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109675042A CN109675042A (zh) | 2019-04-26 |
CN109675042B true CN109675042B (zh) | 2021-03-23 |
Family
ID=66195447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910105492.3A Active CN109675042B (zh) | 2019-02-01 | 2019-02-01 | 用于治疗和/或预防流感的组合物、方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109675042B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384795A (zh) * | 2019-08-29 | 2019-10-29 | 山西锦波生物医药股份有限公司 | 一种预防和控制流感病毒的喷雾及其制备方法 |
CN111053892B (zh) * | 2019-12-24 | 2023-11-17 | 山西锦波生物医药股份有限公司 | 一种广谱抗肠道病毒的蛋白类药物及其应用 |
CN111747944B (zh) * | 2020-07-13 | 2022-09-30 | 复旦大学 | 广谱抗包膜病毒化合物、组合物及其应用 |
CN112316152B (zh) * | 2020-11-04 | 2023-05-02 | 山西锦波生物医药股份有限公司 | 经酸酐修饰的蛋白质抑制冠状病毒的方法 |
CN113755456B (zh) * | 2021-09-08 | 2022-02-15 | 北京大学 | 一种复制缺陷型耐药流感病毒及其核酸节段重组率检测方法 |
CN116763902B (zh) * | 2023-08-17 | 2023-11-03 | 北京悦康科创医药科技股份有限公司 | 抗冠状病毒脂肽在治疗和预防流行性感冒中的用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015316A1 (en) * | 1991-03-11 | 1992-09-17 | Rijksuniversiteit Te Groningen | Modified proteins and their use for controlling viral infections |
WO2004052931A1 (en) * | 2002-12-06 | 2004-06-24 | Delta Biotechnology Limited | Negatively charged antiviral protein conjugates |
WO2011116963A3 (en) * | 2010-03-24 | 2012-06-07 | Lipotec S.A. | Lipid nanoparticle capsules |
CN102631666A (zh) * | 2012-03-14 | 2012-08-15 | 杨霞 | 一种预防和控制人乳头瘤病毒感染的生物制剂的制备方法 |
CN108721281A (zh) * | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新的抗病毒药物及其应用 |
-
2019
- 2019-02-01 CN CN201910105492.3A patent/CN109675042B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015316A1 (en) * | 1991-03-11 | 1992-09-17 | Rijksuniversiteit Te Groningen | Modified proteins and their use for controlling viral infections |
WO2004052931A1 (en) * | 2002-12-06 | 2004-06-24 | Delta Biotechnology Limited | Negatively charged antiviral protein conjugates |
WO2011116963A3 (en) * | 2010-03-24 | 2012-06-07 | Lipotec S.A. | Lipid nanoparticle capsules |
CN102631666A (zh) * | 2012-03-14 | 2012-08-15 | 杨霞 | 一种预防和控制人乳头瘤病毒感染的生物制剂的制备方法 |
CN108721281A (zh) * | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新的抗病毒药物及其应用 |
Non-Patent Citations (2)
Title |
---|
Inhibition of Influenza Virus Fusion by Polyanionic Proteins;Pieter Schoen,等;《Biochemical Pharmacology》;19970404;第53卷;第996页右栏、摘要、图2、第998页右栏 * |
Pieter Schoen,等.Inhibition of Influenza Virus Fusion by Polyanionic Proteins.《Biochemical Pharmacology》.1997,第53卷第995-1003页. * |
Also Published As
Publication number | Publication date |
---|---|
CN109675042A (zh) | 2019-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109675042B (zh) | 用于治疗和/或预防流感的组合物、方法和用途 | |
Kuwano et al. | HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. | |
CN112316152B (zh) | 经酸酐修饰的蛋白质抑制冠状病毒的方法 | |
US20140030229A1 (en) | New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer | |
RU2505306C2 (ru) | Композиция для профилактики и лечения вирусных инфекций | |
AU2016308917A1 (en) | Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus | |
US20180256703A1 (en) | Single-Cycle Virus for the Development of Canine Influenza Vaccines | |
CN111265508B (zh) | 双醋瑞因在制备抗病毒药物及治疗病毒感染中的用途 | |
Kangro et al. | Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents | |
US20090186101A1 (en) | Use of Elderberry Extract | |
US20180177860A1 (en) | Vaccine containing virus inactivated by green tea extract, and preparation method therefor | |
Nurpeisova et al. | Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine | |
RU2701953C1 (ru) | Способ получения поливалентной вакцины от гриппа | |
KR20180054091A (ko) | 인플루엔자 바이러스 표면 단백질 헤마글루티닌 단량체를 포함하는 오소믹소바이러스에 대한 항원 조성물 | |
Morozova et al. | Antiviral properties and toxicity of Ag-cystine complex | |
CN113975299A (zh) | 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用 | |
Sharti et al. | Double-stranded rna activated caspase oligomerizer (Draco): Designing, subcloning, and antiviral investigation | |
Bose et al. | Induced pluripotent stem cell derived human lung organoids to map and treat the SARS-CoV2 infections in vitro | |
US20240108713A1 (en) | Novel replication deficient influenza a virus inducing high levels of type i interferon | |
CN102961757A (zh) | 携带双链rna靶抗原和中和抗原的假病毒颗粒疫苗 | |
RU2464311C1 (ru) | Штамм вируса гриппа для производства живой гриппозной интраназальной вакцины для взрослых и детей | |
WO2022205822A1 (zh) | 一种抑制新型冠状病毒感染的抗菌肽及其用途 | |
RU2681439C1 (ru) | Вирусоподобная частица вируса гриппа и способ ее получения | |
RU2706544C1 (ru) | Концентрат вакцины от гриппа и способ его получения | |
US20220401554A1 (en) | Use of membrane inhibitors to enhance vaccine development against enveloped viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190729 Address after: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant after: Shanxi Jin Bo Biomedics Inc. Address before: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant before: Shanxi Jin Bo Biomedics Inc. Applicant before: Fudan University |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 030032 No.18, Jinbo street, Tanghuai Park, Taiyuan comprehensive reform demonstration zone, Taiyuan City, Shanxi Province Applicant after: SHANXI JINBO BIOMEDICAL Co.,Ltd. Address before: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant before: SHANXI JINBO BIOMEDICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |